Phase I Study of a Statin + Erlotinib for Advanced Solid Malignancies With Focus on Squamous Cell Carcinomas and NSCLC

Inclusion Criteria: * Histologically or cytologically documented advanced and/or metastatic incurable tumor (especially squamous cell carcinoma or NSCLC). * Clinically or radiologically documented (measurable or evaluable)disease. * 18 years or older and less than 70 years of age. * ECOG performance status: 0, 1 or 2 * No previous therapy with EGFR inhibitor (monoclonal antibody or TKI). * Must have recovered from any treatment related toxicities prior to registration. * Curative radiotherapy must be completed at least 3 months prior to registration * Palliative radiotherapy is permitted providing a minimum of 14 days have elapsed between the end of radiotherapy and registration onto the study and patients have recovered from any acute toxic effects from radiation prior to registration. * Previous surgery is permitted provided wound healing has occurred and at least 14 days have elapsed prior to registration if surgery was major. * Adequate hematopoietic, hepatic and renal function defined as follows: hemoglobin \>= 90g/L, platelets \> 100 x 10\^9/L, bilirubin \<1.5 x ULN, ALT or AST \<1.5 x ULN, proteinuria \< grade 1, normal thyroid function (normal TSH or free T4 level after correction), serum creatinine institution normal limits or calculated creatinine clearance \> 60 mls/min (except for patients with cervical cancer who require a creatinine clearance of 72 mls/min.) * Women must be post menopausal, surgically sterile or use two reliable forms of contraception. Women of…